Table 4. Changes in Neurologic Signs and Symptoms for Women Receiving Sagopilone (N = 15)^a.

Study Time Point	Overall Status of Neurologic Signs and Symptoms (n)			Worsening of ≥1 Neurologic Domainb
	Improved	Stable	Worsening
Midtherapy	1	8	2c	7 (of 11)
Progression/withdrew from study	0	5	9c	10 (of 14)d

^aThree patients had progression at second assessment and did not have “midtherapy” evaluations; 1 patient did not have assessments beyond baseline.

^bDomains included level of consciousness, symptoms, cranial nerves, language, strength, sensation, and ataxia.

^cAt midtherapy and progression in 1 woman and 5 women, respectively, the signs and symptoms were felt to be possibly, probably, or definitely related to therapy.

^dSeven of these patients had worsening overall status.